Subscribe by Email

About the Blog

The Active Ingredient features expert insights and commentary from leaders of ZS Associates' global pharmaceuticals practice.

Search by Topic

see all

Winning Isn’t Easy: What Biopharma Companies Can Do to Find Success in a Crowded Marketplace

Posted by Ross Shahinian on Wed, Feb 07, 2018

Christina Corridon co-wrote this blog post with Ross Shahinian.

In 2017, there were 46 novel drug approvals in the U.S., according to the FDA. However, the majority (67%) of these drug approvals represent later-to-market entrants that will be vying for share in an increasingly competitive landscape. For example, take Verzenio, Lilly’s CDK-inhibitor for HR-positive breast cancer, which was third to market after Pfizer’s Ibrance and Novartis’s Kisqali. Or Steglatro, the Merck and Pfizer fourth-to-market SGLT-2 drug, which came in after Invokana, Farxiga and Jardiance.

Read More

Topics: Pharma, Biosimilars, Differentiation, Competition, biopharma, competitive advantage, pharma companies, drug approvals, market share

Subscribe to The Active Ingredient
SUBSCRIBE

Get 'THE ACTIVE INGREDIENT' Updates

Subscribe to receive email notifications whenever new blog posts are published.

×